Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.1
(-2.36%)
SEK 3.1
(-2.36%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 12.74 Million SEK | -66.21% |
| 2022 | 37.71 Million SEK | 46.97% |
| 2021 | 25.65 Million SEK | 32.82% |
| 2020 | 19.31 Million SEK | 46.75% |
| 2019 | 13.16 Million SEK | 16.03% |
| 2018 | 11.34 Million SEK | 156.73% |
| 2017 | 4.41 Million SEK | 58.33% |
| 2016 | 2.79 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 29.24 Million SEK | 129.48% |
| 2024 Q2 | 47.26 Million SEK | 61.63% |
| 2023 Q2 | 33.62 Million SEK | -5.54% |
| 2023 FY | 12.74 Million SEK | -66.21% |
| 2023 Q4 | 12.74 Million SEK | -41.54% |
| 2023 Q3 | 21.8 Million SEK | -35.16% |
| 2023 Q1 | 35.59 Million SEK | -5.61% |
| 2022 FY | 37.71 Million SEK | 46.97% |
| 2022 Q4 | 37.71 Million SEK | 58.48% |
| 2022 Q3 | 23.79 Million SEK | -7.67% |
| 2022 Q2 | 25.77 Million SEK | -4.92% |
| 2022 Q1 | 27.1 Million SEK | 5.64% |
| 2021 Q2 | 21.84 Million SEK | -43.45% |
| 2021 Q1 | 38.62 Million SEK | 99.94% |
| 2021 Q3 | 23.79 Million SEK | 8.93% |
| 2021 Q4 | 25.65 Million SEK | 7.84% |
| 2021 FY | 25.65 Million SEK | 32.82% |
| 2020 FY | 19.31 Million SEK | 46.75% |
| 2020 Q2 | 25.58 Million SEK | 70.12% |
| 2020 Q1 | 15.03 Million SEK | 14.24% |
| 2020 Q3 | 18.34 Million SEK | -28.31% |
| 2020 Q4 | 19.31 Million SEK | 5.33% |
| 2019 Q4 | 13.16 Million SEK | 38.48% |
| 2019 FY | 13.16 Million SEK | 16.03% |
| 2019 Q2 | 11.34 Million SEK | 21.01% |
| 2019 Q1 | 9.37 Million SEK | 110.82% |
| 2019 Q3 | 9.5 Million SEK | -16.21% |
| 2018 Q2 | 4.41 Million SEK | 0.0% |
| 2018 Q4 | 4.44 Million SEK | 0.0% |
| 2018 FY | 11.34 Million SEK | 156.73% |
| 2017 FY | 4.41 Million SEK | 58.33% |
| 2016 FY | 2.79 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 88.044% |
| Ziccum AB (publ) | 6.38 Million SEK | -99.499% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -440.229% |
| BioArctic AB (publ) | 139.5 Million SEK | 90.865% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 63.171% |
| Mendus AB (publ) | 51.22 Million SEK | 75.122% |
| Genovis AB (publ.) | 98.04 Million SEK | 87.002% |
| Intervacc AB (publ) | 21.68 Million SEK | 41.218% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 52.284% |
| Active Biotech AB (publ) | 13.4 Million SEK | 4.896% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 89.721% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 20.928% |
| Aptahem AB (publ) | 8.99 Million SEK | -41.634% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 68.81% |
| Kancera AB (publ) | 17.97 Million SEK | 29.113% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 72.404% |
| Fluicell AB (publ) | 8.91 Million SEK | -42.95% |
| Saniona AB (publ) | 86.08 Million SEK | 85.196% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -147.073% |
| Biovica International AB (publ) | 34.76 Million SEK | 63.345% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -9.222% |
| AcouSort AB (publ) | 10.37 Million SEK | -22.798% |
| Xintela AB (publ) | 14.01 Million SEK | 9.069% |
| Abliva AB (publ) | 16.78 Million SEK | 24.057% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 94.062% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -10.156% |
| OncoZenge AB (publ) | 1.69 Million SEK | -650.088% |
| Amniotics AB (publ) | 10.54 Million SEK | -20.831% |
| 2cureX AB (publ) | 2.93 Million SEK | -334.208% |
| CombiGene AB (publ) | 4.15 Million SEK | -206.641% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -187.935% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.186% |
| Camurus AB (publ) | 414.81 Million SEK | 96.928% |
| Corline Biomedical AB | 6.78 Million SEK | -87.715% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 79.23% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 33.5% |
| I-Tech AB | 16.2 Million SEK | 21.358% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 98.925% |
| Cyxone AB (publ) | 4.69 Million SEK | -171.496% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 4.382% |
| Biosergen AB | 5.08 Million SEK | -150.619% |
| Cantargia AB (publ) | 54.97 Million SEK | 76.816% |
| NextCell Pharma AB | 13.68 Million SEK | 6.904% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 82.263% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 7.462% |
| Nanologica AB (publ) | 79.32 Million SEK | 83.935% |
| SynAct Pharma AB | 51.83 Million SEK | 75.414% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -60.322% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -145.315% |
| LIDDS AB (publ) | 3.75 Million SEK | -239.297% |
| Lipum AB (publ) | 7.53 Million SEK | -69.063% |
| BioInvent International AB (publ) | 90.45 Million SEK | 85.911% |
| Alzinova AB (publ) | 9.33 Million SEK | -36.577% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 92.982% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -610.368% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 31.091% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -232.048% |
| Simris Alg AB (publ) | 148.93 Million SEK | 91.443% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 82.08% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 97.357% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -75.537% |